A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
When asked what the ideal patient is for the 4-drug combination of lenalidomide, bortezomib, and dexamethasone plus daratumumab, Fonseca responded that is the wrong question; rather, clinicians should consider if there are any patients who should not receive this regimen.
Minimal residual disease (MRD) testing has become central to myeloma treatment goals. As the most sensitive test for residual disease, MRD negativity is now the most important prognostic factor in myeloma. Four analyses support the predictive value of MRD status. Unknowns remain regarding discontinuing therapy with sustained MRD negativity and escalating therapy for persistent MRD positivity, although Fonseca tests patients routinely after transplant to guide next treatment steps aimed at achieving MRD negativity. While this must be done judiciously, he believes eliminating every myeloma cell should be the primary goal.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More